Product information and disease description Place of product in therapy Disease description Epidemiology

Prevalence of Neovascular age-related macular degeneration

10 evidence topics · 7 sources

Global prevalence: systematic review and meta-analysis of 39 population-based studies

“Analysis of 129,664 individuals (aged 30-97 years), with 12,727 cases from 39 studies, showed the pooled prevalence (mapped to an age range of 45-85 years) of early, late, and any age-related macular degeneration to be 8.01% (95% CrI 3.98-15.49), 0.37% (0.18-0.77), and 8.69% (4.26-17.40), respectively.” (opens the source at this quote in a new tab)
“The projected number of people with age-related macular degeneration in 2020 is 196 million (95% CrI 140-261), increasing to 288 million in 2040 (205-399).” (opens the source at this quote in a new tab)

United States prevalence of late-stage AMD in 2019: Vision and Eye Health Surveillance System

“We estimated there were 1.49 million people 40 years and older (95% UI, 0.97-2.15) living with late-stage AMD, corresponding to a crude prevalence rate of 0.94% (95% UI, 0.62-1.36).” (opens the source at this quote in a new tab)
“For 2019, we estimated that there were 18.34 million people 40 years and older (95% uncertainty interval [UI], 15.30-22.03) living with early-stage AMD, corresponding to a crude prevalence rate of 11.64% (95% UI, 9.71-13.98).” (opens the source at this quote in a new tab)

United States prevalence of neovascular AMD or geographic atrophy in 2000

“The overall prevalence of neovascular AMD and/or geographic atrophy in the US population 40 years and older is estimated to be 1.47% (95% confidence interval, 1.38%-1.55%), with 1.75 million citizens having AMD. The prevalence of AMD increased dramatically with age, with more than 15% of the white women older than 80 years having neovascular AMD and/or geographic atrophy.” (opens the source at this quote in a new tab)

United States projections and share of severe vision loss

“Aging is the greatest risk factor; therefore, the prevalence of AMD in the United States is anticipated to increase to 22 million by the year 2050, whereas the global prevalence is expected to increase to 288 million by the year 2040.” (opens the source at this quote in a new tab)
“Overall, AMD is responsible for an estimated 46% of cases of severe visual loss (visual acuity [VA] 20/200 or worse) in people over age 40 in the United States.” (opens the source at this quote in a new tab)
“the neovascular form is responsible for nearly 90% of the severe VA loss (20/200 or worse) from AMD because of its natural history.” (opens the source at this quote in a new tab)

Europe prevalence: systematic review and meta-analysis

“Our pooled prevalence estimate of early or intermediate AMD and any late AMD in those 60 years and older was 25.3% (95% CI 18.0% to 34.4%) and 2.4% (95% CI 1.8% to 3.3%), respectively.” (opens the source at this quote in a new tab)

Global prevalence of AMD-related vision impairment: Global Burden of Disease Study 2021

“Globally, the number of individuals with vision impairment due to AMD more than doubled, rising from 3·64 million (95% uncertainty inverval [UI] 3·04-4·35) in 1990 to 8·06 million (6·71-9·82) in 2021.” (opens the source at this quote in a new tab)
“The burden of vision impairment due to AMD is projected to increase to about 21·34 million in 2050.” (opens the source at this quote in a new tab)

Global prevalence of the neovascular subtype and of geographic atrophy

“Eight (21%) of the 39 studies provided information on geographic atrophy and neovascular subtypes. Subgroup analysis showed similar overall prevalence of geographic atrophy (0·44%, 95% CrI 0·15–1·36) and neovascular age-related macular degeneration (0·46%, 0·18–1·08).” (opens the source at this quote in a new tab)
“Europeans had a higher prevalence of geographic atrophy (1·11%, 95% CrI 0·53–2·08) than Africans (0·14%, 0·04–0·45), Asians (0·21%, 0·04–0·87), and Hispanics (0·16%, 0·05–0·46).” (opens the source at this quote in a new tab)

Projected cases by world region in 2040

“Europe is expected to be second to Asia in the number of projected cases (69 million [40–109] in 2040), followed by Africa (39 million [12–93]), Latin America and the Caribbean (39 million [15–82]), North America (25 million [15–38]), and Oceania (2 million [1–5]).” (opens the source at this quote in a new tab)

Age at which late-stage prevalence rises most steeply

“Prevalence of late disease in populations with European ancestry increased most rapidly after age 75 years, with a similar trend seen in Europe and Oceania regions.” (opens the source at this quote in a new tab)

Neovascular share of prevalent late-stage disease

“Although neovascular AMD accounts for only two thirds of prevalent late-stage cases, it is responsible for over 80% of legal blindness due to AMD.” (opens the source at this quote in a new tab)